| Date | Title | Description |
| 08.07.2026 | Defense Tech Soars: Quantum Systems Lands $1.2 Billion Amid Industry Boom | Quantum Systems clinched $1.2 billion in Series D funding, achieving an $8 billion valuation. Blackstone, Noteus, Airbus, and Advent co-led the round. The German company specializes in AI-powered autonomous drones and advanced defense syste... |
| 03.07.2026 | Quantum Systems raises $1.2B, IQM becomes first European quantum company on major US exchange, and European startup funding in June | This week, we tracked more than 55 tech funding deals worth over €1.6 billion and over 10 exits, M&A transactions, rumours, and related news stories across Europe.
If email is more your thing, you can always subscribe to our newsletter ... |
| 02.07.2026 | Ysios Capital anuncia una nueva desinversión tras la adquisición de Memo Therapeutics por Ipsen | Ysios Capital, gestora europea líder en venture capital en ciencias de la vida, ha anunciado una nueva desinversión de su fondo Ysios BioFund III tras el acuerdo de adquisición de su participada Memo Therapeutics AG por parte de la biofarma... |
| 01.07.2026 | Ipsen to acquire Memo Therapeutics for up to EUR 700 million |
French biopahram company Ipsen and Schlieren-based Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeu... |
| 24.04.2026 | Kurma Partners: €215 Million Biofund IV Closes As Total AUM Reach €1 Billion | Kurma Partners, a Paris-based European healthcare venture capital firm and Eurazeo group company, has announced the final closing of Biofund IV at €215 million, bringing total assets under management across all Kurma Partners franchises to ... |
| 09.02.2026 | Memo Therapeutics enters into a collaboration with CSL |
Under the Collaboration and Option Agreement, Schlieren-based Memo Therapeutics AG (MTx) will develop recombinant polyclonal IgG products, leveraging its proprietary DROPZYLLA® technology platform for cloning human antibody repertoires and... |
| 23.12.2025 | Regulatory approval and a milestone payment for Swiss biotechs |
The European Commission has granted orphan designation in the European Union (EU) for Memo Therapeutics’ potravitug, a highly potent human BK polyomavirus (BKPyV)-neutralizing antibody for the treatment of BKPyV infection in kidney transpl... |
| 07.11.2025 | Development milestones and financing for biotech companies |
Timeline, a longevity biotech company behind Mitopure® (Urolithin A) — a postbiotic that stimulates mitophagy, the body’s cellular recycling process critical for mitochondrial and metabolic health — has published a new clinical study on im... |
| 02.09.2025 | Regulatory milestones and clinical progress for Swiss biotechs |
TOLREMO therapeutics AG, a Swiss biotech startup redefining cancer treatment by targeting non-oncogene addiction, has obtained two Fast Track designations from the U.S. Food and Drug Administration (FDA) for its lead candidate, TT125-802 f... |
| 23.07.2025 | Three biotechs on the verge of launching potential treatments |
Berlin Heals, a pioneer in bioelectric medicine for the treatment of heart failure, announced the publication of a new peer-reviewed study titled "Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in... |
| 04.11.2024 | Memo Therapeutics AG Appoints Frits van Alphen, MD as Chief Development Officer | PRESS RELEASE
Frits is an industry veteran with a proven track record in nephrology drug development, including the successful development of Velphoro® and Ferinject® at Vifor Pharma
Schlieren / Zurich, Switzerland, 4 November, 2024 – Memo ... |
| 01.11.2024 | Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients | Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the las... |
| 01.11.2024 | Memo Therapeutics AG Announces Last Patient Enrolled in Phase II Clinical Trial of Potravitug for Treatment of BK Viremia in Kidney Transplant Patients | Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the las... |
| 03.10.2024 | European VC firm Kurma closes first $154M of largest planned fund, eyes up to 20 biotech investments | European VC firm Kurma Partners has unveiled its latest biotech fund, with 140 million euros ($154 million) raised so far and three biotech beneficiaries already named.
Kurma plans to raise a total of 250 million euros ($276 million) for th... |
| 27.08.2024 | Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy | PRESS RELEASE
Alex Bastian joins Memo Therapeutics AG as VP Commercial Strategy Seasoned commercial leader with significant international experience Joins ahead of lead development candidate Potravitug entering Phase III trial
Schlieren / Z... |
| 07.05.2024 | Memo Therapeutics Raises CHF 20M; Increases Series C to CHF 45M | Memo Therapeutics, a Schlieren, Zurich, Switzerland-based late-stage biotech company developing a BKV-neutralizing antibody for BKV infection in kidney transplantation, raised additional CHF 20M bringing the total amount of its Series C to ... |
| 07.05.2024 | Memo Therapeutics increases Series C financing to CHF 45 million | PRESS RELEASE
Memo Therapeutics increases Series C financing to CHF 45 million
Additional CHF 20 million raised from new investors Ysios Capital and Kurma Partners as well as from existing investors
Proceeds will be used to expand Phase II ... |
| 07.05.2024 | Memo Therapeutics raises additional CHF20 million |
Schlieren-based Memo Therapeutics is a late-stage biotech company developing therapeutic antibodies for patients with viral infections and cancer. MTx’s lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat B... |
| 06.12.2023 | Leadership changes with some promotions | |
| 02.11.2023 | Memo Therapeutics Raises CHF 25 Million Series C Financing | |
| 02.11.2023 | Memo Therapeutics Raises CHF 25M in Series C Financing | Memo Therapeutics, a Schlieren / Zurich, Switzerland-based late-stage biotech company, raised CHF 25M in Series C funding.
The round was led by Pureos Bioventures, with participation from xisting investors Swisscanto, Vesalius Biocapital, A... |
| 03.05.2023 | Memo Therapeutics kicks off phase II/III trials after receiving FDA Fast Track Designation | |
| 13.04.2023 | Preventing the Next Pandemic: The Innovative Solutions Leading the Way | The COVID-19 pandemic created an unprecedented health and societal crisis for many of us across the world. Its death toll estimates place it among history’s deadliest plagues. Despite having much more advanced economic, healthcare, and tech... |
| 25.01.2023 | Positive results for new drug targeting kidney transplant recipients | |
| 01.11.2022 | Ono Pharmaceutical relies on Memo Therapeutics for antibody discovery | |
| 01.06.2022 | Memo Therapeutics enters clinical stage with an antibody against BK virus infection | |
| 16.02.2022 | Memo Therapeutics raises CHF 37 million in an oversubscribed Series B fundraising round | Memo Therapeutics raises CHF 37 million in an oversubscribed Series B fundraising round 16.02.2022 09:27, Isabelle Mitchell linkedIn facebook twitter instagram youtube -->
Memo Therapeutics AG (“MTx”), an innovator in the field of antibo... |
| 16.02.2022 | Memo Therapeutics raises CHF 23 million | |
| 16.02.2022 | Memo Therapeutics Raises CHF23M Extension; Closes CHF37M Series B Financing | Memo Therapeutics AG, a Schlieren, Switzerland-based innovator in the field of antibody discovery and development, closed a Series B financing round of CHF37m after securing an additional CHF23m.
The round was led by Swisscanto Invest and i... |
| 15.12.2021 | Memo Therapeutics gets CHF 10.5 million from the Swiss government to clinically develop their antibody against COVID-19 | Memo Therapeutics gets CHF 10.5 million from the Swiss government to clinically develop their antibody against COVID-19 15.12.2021 20:35, Guillaume Tinsel linkedIn facebook twitter instagram youtube -->
Memo Therapeutics, an innovator in... |
| 13.12.2021 | Federal government signs four contracts for the development of COVID-19 medicines | |
| 20.07.2021 | Startups welcome legendary board members aboard | DiNAQor – three prominent cardiovascular industry and Academic Experts
Louis G. Lange, Steven Zelenkofske, and Silke Rickert-Sperling, some of the most renowned cardiovascular industry and academic experts are joining the board of directors... |
| 17.05.2021 | Memo Therapeutics antibodies show efficacy against Covid-19 variants | Using its microfluidic, single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery, Memo Therapeutics can discover novel antibodies at high speed, efficiency and sensitivity derived ... |
| 17.05.2021 | Memo Therapeutics antibodies show efficacy against Covid-19 variants | |
| 09.11.2020 | Switzerland's Memo Therapeutics lands €13M | Biotech startup Memo Therapeutics has raised 14 million Swiss francs (around €13 million) in a led by Swisscanto Invest. The funds will be used in part to advance Memo's antibody candidate for COVID-19 through to Phase II clinical studies.
... |
| 06.11.2020 | Memo Therapeutics raises CHF14 Million for Covid antibody development | Memo Therapeutics AG, an innovator in the field of antibody discovery and immune repertoire analysis. Its antibody discovery platform uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enab... |
| 06.11.2020 | Memo Therapeutics raises CHF14 Million for Covid antibody development | |
| 06.11.2020 | Memo Therapeutics Raises CHF 14M in Series B Financing Round | Memo Therapeutics AG, a Schliren, Switzerland-based antibody discovery and immune repertoire analysis company, raised CHF 14m in Series B financing.
The round was led by Swisscanto Invest by Zürcher Kantonalbank and included BERNINA BioInve... |
| 06.11.2020 | Swiss biotech Memo Therapeutics lands €13.9 million to advance its COVID-19 antibody treatment | Swiss company Memo Therapeutics AG, an innovator in the field of antibody discovery and immune repertoire analysis, announced today that the company has raised around €13.9 million in Series B financing. The round was led by Swisscanto Inve... |
| 06.11.2020 | Memo Therapeutics AG : Raises CHF 14 Million in a Series B Financing Round | Memo Therapeutics AG, an innovator in the field of antibody discovery and immune repertoire analysis, announced today that the company has raised CHF 14 million in Series B financing. The round was led by Swisscanto Invest by Zürcher Kanton... |
| 06.11.2020 | Memo Therapeutics receives CHF14M in Series B financing round for COVID-19 antibody development | Memo Therapeutics receives CHF14M in Series B financing round for COVID-19 antibody development 06.11.2020 11:10, Jonatan Masseus linkedIn facebook twitter instagram youtube -->
Schlieren-based Memo Therapeutics is on the hunt for clinic... |
| 04.06.2020 | Memo Therapeutics identifies SARS-CoV-2 neutralizing antibodies | |
| 04.06.2020 | Memo Therapeutics identifies SARS-CoV-2 neutralizing antibodies | Since March, Memo Therapeutics (MTx) has selected the most promising donors from hundreds of Swiss COVID-19 patients. The selection criteria identified patients who had demonstrated a clinical course of COVID-19 indicative of a particularly... |
| 13.05.2020 | Swiss Startups Tackling Corona Virus - COVID-19 | Swiss Startups Tackling Corona Virus - COVID-19 13.05.2020 13:14, Gianmaria Sbetta linkedIn facebook twitter instagram youtube -->
Corona Virus is changing our society, our economy and our lifestyle. Remote working and online collaborati... |
| 28.10.2019 | Memo Therapeutics to receive milestone and royalty payments | |
| 11.09.2019 | One step closer to changing the outcome of renal transplantations | |
| 09.05.2018 | Memo Therapeutics Closes CHF5.0M Series A2 Financing Round | Memo Therapeutics AG, a Basel, Switzerland-based innovator in the field of antibody discovery and human immune repertoire analysis, closed a CHF 5.0m Series A2 financing round.
The round included new investors Schroder Adveq, investiere.ch ... |
| 28.03.2017 | 22 startups selected to pitch at the Swiss Venture Day - reloaded | |
| 23.07.2015 | Memo Therapeutics Closes CHF2.3M Series A Financing | Memo Therapeutics, a Basel/Zurich-based developer of a platform technology for antibody discovery, closed a CHF2.3m Series A financing.
The round by Redalpine and other Swiss investors, including EVA Basel and Zürcher Kantonalbank.
The comp... |
| 22.07.2015 | Memo Therapeutics raises CHF 2.3 million | |
| - | Memo Therapeutics | “Home - Memo Therapeutics AG” |
